Personalized mRNA Cancer Vaccine Clears Phase 3 Hurdle, Cutting Melanoma Recurrence

Moderna and Merck's personalized mRNA cancer vaccine intismeran, combined with their blockbuster immunotherapy Keytruda, met both its primary and key secondary endpoints in a Phase 3 trial for high-risk melanoma — marking the most significant clinical validation yet for individualized cancer immunotherapy.

Plain English

Imagine a cancer vaccine custom-built just for you. Scientists sequenced the unique mutations in each patient's tumor, then designed an mRNA shot that...